Clinical

New research suggests Nestin expression can help distinguish combined hepatocellular-cholangiocarcinomas (CCAs) from hepatocellular carcinomas and intrahepatic cholangiocarcinomas.

Patients receiving the quadruplet therapy have continued to show improved responses and higher rates of minimal residual disease (MRD) negativity.

In the phase 3 trial, Pfizer’s vaccine was 85.7% effective against respiratory syncytial virus (RSV) defined by 3 or more symptoms among older adults.

David Epstein, MD, MBA, an independent consultant, gives an overview of payer considerations surrounding vitiligo.

Vitiligo’s effects on clinical burden and patient quality of life are addressed by Brett King, MD, PhD, and David Rosmarin, MD.

A clinician, advocate, and payer provide their expert knowledge on the multiple modalities of PrEP therapy and how some can be more beneficial than others.

Frank J. Palella, Jr discusses cabotegravir, a recently approved injectable PrEP medication, that was test in the HTPN 083 and -084 trials.

Rohit Uppal, MD, MBA, SFH, outlines unique treatment strategies for various ejection fraction types in the presence of comorbidities.

Offering an effective, tolerable, and chemotherapy-free option for patients with chronic lymphocytic leukemia (CLL), Bruton’s tyrosine kinase (BTK) inhibitors have drastically changed the disease’s landscape.

In this interview with The American Journal of Managed Care®, Sigrun Hallmeyer, MD, medical director of Advocate Lutheran General Hospital’s Cancer Service Line and co-director of medical research at Advocate Aurora Health, in Illinois, touches on several important topics within the melanoma space.

Drs Feldman and Agarwal consider the health disparities commonly seen with patients that have CKD and their impact in the treatment landscape.

Paul Sapia, MHA, focuses on the gaps in care that are seen within CKD treatment.

A significant subset of patients continues to receive chemotherapy monotherapy despite the availability of newer approaches, including programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors.

This subanalysis of data from the ELDERCARE-AF trial investigated the safety and effectiveness of a 15-mg daily dose of the factor Xa inhibitor among older patients who have atrial fibrillation (AFib).

A new review outlines what is known about cardiovascular disease (CVD) risk in patients with systemic lupus erythematosus (SLE) and how that might affect patient care.

Researchers studied data from 5 phase 1 studies that took place between 2012 and 2021, comprising 139 infusions among patients with B-cell acute lymphoblastic leukemia who received chimeric antigen receptor (CAR) T-cell treatment.

The pandemic has changed how care has delivered, but what professionals new to health care know about strategies used to connect with patients in a virtual setting, or the quality of the instruction they receive, is not known.

Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on key areas of HS comprehension and management that warrant further investigation in clinical research.

A study found cystatin C, renal resistance index, and urinary kidney injury molecule-1 were significantly associated with risk of diabetic kidney disease (DKD) in children and adolescents with type 1 diabetes (T1D).

Dr Oskouei explains the indications for adalimumab and the impact of their extrapolation, as well as differences among adalimumab products.

An expert authority explains the treatment selection process for a patient, as well as the different ways to administer PrEP.

Lynne H. Milgram, MD, MBA, CPE, iterates the importance of PrEP as an HIV prevention tactic and how walk away and fill rates are evaluated.

Medical experts discuss benefits of titrating therapies for management of ejection fraction pathologies.

Dr Januzzi analyzes preventive approaches for patients with pre-heart failure, including comorbidity considerations and preliminary testing.

David Rosmarin, MD, discusses the prevalence and incidence of vitiligo across a diverse patient population.

A panel of experts open a discussion surrounding vitiligo, including the definition and nature of the disease.

Edward Arrowsmith, MD, concludes with his thoughts on developing therapies and how they are implemented into clinical pathways for NSCLC treatment.

Dr Arrowsmith discusses the role immune checkpoint inhibitors play in NSCLC therapy, both as monotherapy and in combination therapy.

The FDA Wednesday approved betibeglogene autotemcel (Zynteglo), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Dr Feldman describes the populations that are most at risk of developing CKD.